Nanobiotix Announces Extraordinary General Meeting on September 1
Nanobiotix will hold an extraordinary general meeting on September 1, 2023, to seek shareholder approval for a new share issuance to Johnson & Johnson Innovation as part of a previously announced agreement.
Nanobiotix, a clinical-stage biotechnology company focused on cancer treatments, has announced an extraordinary general meeting (EGM) to be held on September 1, 2023. The meeting will take place at the company's headquarters in Paris at 2:00 PM CEST.
The primary agenda item for the EGM is the approval of a new share issuance of up to 959,638 shares to Johnson & Johnson Innovation - JJDC, Inc. This issuance is in exchange for an initial tranche payment of $5 million, as part of agreements detailed in a July 10, 2023 press release.
The company is developing physics-based approaches to expand treatment options for cancer patients. Its lead product candidate, NBTXR3, has received marketing authorization in Europe for the treatment of soft tissue sarcomas under the brand name Hensify®.
Further details regarding the meeting, including instructions for participation and voting, are available on the Nanobiotix website. The company was first listed on Euronext Paris in 2012 and began trading on the Nasdaq Global Select Market in December 2020.